Welcome to our dedicated page for Globus Med SEC filings (Ticker: GMED), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Globus Medical, Inc. (NYSE: GMED) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a publicly traded musculoskeletal medical device manufacturer, Globus Medical files annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K that describe its operations, risk factors, financial performance, and material events.
Recent Form 8-K filings from Globus Medical have reported preliminary and final net sales and operating results for specific quarters and fiscal years, leadership transitions at the President, Chief Executive Officer, and Chief Financial Officer roles, and other significant corporate developments. These filings often reference earnings press releases furnished as exhibits, which include details on worldwide net sales, U.S. and international performance, non-GAAP financial measures, and guidance for future periods.
Through its filings, Globus Medical also explains its use of non-GAAP metrics such as non-GAAP adjusted EBITDA, non-GAAP net income, non-GAAP diluted earnings per share, non-GAAP gross profit, free cash flow, constant currency net sales growth, and base business sales excluding contributions from recent acquisitions like Nevro Corp. and its subsidiaries. The company describes how these measures adjust for items such as litigation provisions, amortization of intangibles, merger and acquisition-related costs, restructuring-related costs, certain foreign currency impacts, bargain purchase gains, and specific tax effects.
On this page, Stock Titan pairs Globus Medical’s raw SEC documents with AI-powered summaries that highlight the key points of lengthy filings. Users can quickly see what changed in a new 10-K or 10-Q, how management characterizes performance in 8-K earnings releases, and where non-GAAP adjustments have a material impact. The platform also surfaces real-time updates from EDGAR, helping investors follow new filings as they are posted and review the company’s regulatory history in one place.
Globus Medical Senior Vice President and CFO Kyle Kline received a grant of 30,000 stock options to buy Class A common stock at an exercise price of $94.15 per share. The options were granted on January 21, 2026 and were reported as directly owned by Kline. They vest over a four-year period, with one-quarter vesting on January 1, 2027 and the remaining three-quarters vesting in equal monthly installments of 1/48 of the grant each month thereafter, ending on the stated expiration date of January 21, 2036.
Globus Medical Inc. reported that Executive Chairman and director Paul David C, who is also a 10% owner, received a grant of stock options. On January 21, 2026, he was awarded 100,000 stock options to buy Class A common stock at an exercise price of $94.15 per share, with the options themselves granted at a cost of $0.
The options vest over four years, with one quarter vesting on January 1, 2027 and the remaining three quarters vesting in equal monthly installments over the following three years. After this grant, he beneficially owns 100,000 derivative securities directly in the form of these options.
Globus Medical Inc. director Douglas Robert Andrew received a new stock option grant. On January 21, 2026, he was awarded options to buy 15,000 shares of Class A common stock at an exercise price of $94.15 per share. The filing shows these options were granted for no cash payment at grant.
According to the disclosure, the options will vest on January 1, 2027, meaning they become exercisable on that date, and they expire on January 21, 2036 if not exercised. Following this grant, he beneficially owns 15,000 derivative securities directly in the form of these options.
Globus Medical director Dan Lemaitre received a new stock option grant. On January 21, 2026, he was awarded options to buy 15,000 shares of Class A common stock at an exercise price of $94.15 per share, with no cost reported for the options themselves. These options will vest on January 1, 2027 and expire on January 21, 2036. Following this grant, Lemaitre beneficially owns 15,000 derivative securities directly through this option award.
Globus Medical director Ann D. Rhoads received a new stock option award. On January 21, 2026, she was granted options to purchase 15,000 shares of Globus Medical Class A common stock at an exercise price of $94.15 per share. The options were granted at a price of $0 for the derivative itself and are held directly. They will vest on January 1, 2027 and are scheduled to expire on January 21, 2036, giving her a long-term incentive tied to the company’s share performance.
Globus Medical Inc. director James R. Tobin received a grant of stock options on January 21, 2026. The award covers 15,000 stock options to buy Class A common stock at an exercise price of $94.15 per share, with no purchase price for receiving the options themselves.
According to the filing, these options will vest on January 1, 2027 and expire on January 21, 2036 if not exercised earlier. After this grant, Tobin holds 15,000 derivative securities directly, all from this option award. This represents routine equity-based compensation that aligns the director’s interests with the company’s long-term share performance.
Globus Medical Inc. filed an insider trading report showing a new stock option grant to director Stephen T. Zarrilli. On January 21, 2026, he received options to buy 15,000 shares of Class A common stock at an exercise price of $94.15 per share. The grant was recorded at a price of $0 because it reflects an award, not a purchase in the market. These options are held directly and will vest on January 1, 2027, with an expiration date of January 21, 2036.
Globus Medical Inc. director John A. DeFord reported a grant of stock options linked to the company’s Class A common stock. On January 21, 2026, he received 15,000 stock options with an exercise price of $94.15 per share and no cost at grant. According to the disclosure, these options will vest on January 1, 2027, and DeFord now beneficially owns 15,000 derivative securities directly following this transaction.
Globus Medical Inc. granted stock options to director Dan Wolterman. On January 21, 2026, he received options to buy 15,000 shares of Class A common stock at an exercise price of $94.15 per share. These options were granted at no cost to him and are held as a direct ownership position.
The options will vest on January 1, 2027, meaning they become exercisable on that date and remain outstanding until their expiration on January 21, 2036. Following this grant, Wolterman beneficially owns 15,000 derivative securities in the form of these stock options.
Globus Medical Inc. director David D. Davidar received a stock option grant for 15,000 derivative securities tied to Class A common stock. The options were granted on January 21, 2026 at a conversion or exercise price of $94.15 per share and had no purchase price for the derivative security itself. Following this grant, 15,000 derivative securities are beneficially owned on a direct basis.
The options will vest on January 1, 2027 and are scheduled to expire on January 21, 2036. Each option represents the right to buy one share of Class A common stock, so the grant covers 15,000 underlying shares.